Prognostic relevance of gene amplifications and coamplifications in breast cancer

Cancer Research

Volumn 64, Issue 23, 2004, Pages 8534-8540

  Al Kuraya, Khawla ^a,b   Schraml, Peter ^b   Torhorst, Joachim ^b   Tapia, Coya ^b   Zaharieva, Boriana ^c   Novotny, Hedvika ^b   Spichtin, Hanspeter ^d   Maurer, Robert ^e   Mirlacher, Martina ^b   Köchli, Ossi ^f   Zuber, Markus ^g   Dieterich, Holger ^h   Mross, Friedrich ⁱ   Wilber, Kim ^j   Simon, Ronald ^b   Sauter, Guido ^b  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b UNIVERSITY OF BASEL   (Switzerland)

^c MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^d Institute of Clinical Pathology   (Switzerland)

^e TRIEMLI HOSPITAL   (Switzerland)

^f Praxis Dr Köchli   (Switzerland)

^g KANTONSSPITAL   (Switzerland)

^h Frauenklinik Rheinfelden   (Germany)

ⁱ Kreiskrankenhaus Lörrach   (Germany)

^j ABBOTT LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CCND1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GENE PRODUCT; MYC PROTEIN; PROGESTERONE RECEPTOR; PROTEIN MDM2; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GRADING; CANCER SURVIVAL; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE AMPLIFICATION; GENE FREQUENCY; GENETIC STABILITY; HUMAN; HUMAN TISSUE; MEDULLARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS;

BREAST NEOPLASMS; CYCLIN D1; GENE AMPLIFICATION; GENE DOSAGE; GENES, ERBB-1; GENES, ERBB-2; GENES, MYC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NUCLEAR PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2;

EID: 9244222241     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1945     Document Type: Article

References (57)

1. Kallioniemi OP, Kallioniemi A, Kurisu W, et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA 1992;89:5321-5.
2. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science (Wash D C) 1985;229:974-6.
3. Berns EM, Klijn JG, van Staveren IL, Portengen H, Noordegraaf E, Foekens JA. Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors. Eur J Cancer 1992;28:697-700.
4. Rummukainen JK, Salminen T, Lundin J, Kytola S, Joensuu H, Isola JJ. Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array. Mod Pathol 2001;14:1030-5.
5. Anzick SL, Kononen J, Walker RL, et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science (Wash D C) 1997;277:965-8.
6. Courjal F, Cuny M, Rodriguez C, et al. DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours. Br J Cancer 1996;74:1984-9.
7. Barlund M, Forozan F, Kononen J, et al. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J Natl Cancer Inst (Bethesda) 2000;92:1252-9.
8. Luoh SW, Venkatesan N, Tripathi R. Overexpression of the amplified Pip4k2beta gene from 17q11-12 in breast cancer cells confers proliferation advantage. Oncogene 2004;23:1354-63.
9. Hui R, Campbell DH, Lee CS, et al. EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer. Oncogene 1997;15:1617-23.
10. Bellacosa A, de Feo D, Godwin AK, et al. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 1995;64:280-5.
11. Jarvinen TA, Tanner M, Barlund M, Borg A, Isola J. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 1999;26:142-50.
12. Bautista S, Theillet C. CCND1 and FGFR1 coamplification results in the colocalization of 11q13 and 8p12 sequences in breast tumor nuclei. Genes Chromosomes Cancer 1998;22:268-77.
13. Ro J, North SM, Gallick GE, Hortobagyi GN, Gutterman JU, Blick M. Amplified and overexpressed epidermal growth factor receptor gene in uncultured primary human breast carcinoma. Cancer Res 1988;48:161-4.
14. Knuutila S, Autio K, Aalto Y. Online access to CGH data of DNA sequence copy number changes. Am J Pathol 2000;157:689.
15. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
16. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998;16:413-28.
17. Borg A, Baldetorp B, Ferno M, Olsson H, Sigurdsson H. c-myc amplification is an independent prognostic factor in postmenopausal breast cancer. Int J Cancer 1992;51:687-91.
18. Champeme MH, Bieche I, Hacene K, Lidereau R. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer. Mod Pathol 1994;7:900-5.
19. Persons DL, Borelli KA, Hsu PH. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Mod Pathol 1997;10:720-7.
20. Deming SL, Nass SJ, Dickson RB, Trock BJ. C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer 2000;83:1688-95.
21. Naidu R, Wahab NA, Yadav M, Kutty MK. Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction. Int J Mol Med 2002;9:189-96.
22. Berns EM, Klijn JG, van Putten WL, van Staveren IL, Portengen H, Foekens JA. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res 1992;52:1107-13.
23. Scorilas A, Trangas T, Yotis J, Pateras C, Talieri M. Determination of c-myc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis. Br J Cancer 1999;81:1385-91.
24. Schlotter CM, Vogt U, Bosse U, Mersch B, Wassmann K. C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer. Breast Cancer Res 2003;5:R30-6.
25. Gutman M, Ravia Y, Assaf D, Yamamoto T, Rozin R, Shiloh Y. Amplification of c-myc and c-erbB-2 proto-oncogenes in human solid tumors: frequency and clinical significance. Int J Cancer 1989;44:802-5.
26. Cuny M, Kramar A, Courjal F, et al. Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res 2000;60:1077-83.
27. Seshadri R, Lee CS, Hui R, McCaul K, Horsfall DJ, Sutherland RL. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Clin Cancer Res 1996;2:1177-84.
28. Naidu R, Wahab NA, Yadav MM, Kutty MK. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters. Oncol Rep 2002;9:409-16.
29. Courjal F, Cuny M, Simony-Lafontaine J, et al. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res 1997;57:4360-7.
30. McCann AH, Kirley A, Carney DN, et al. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Br J Cancer 1995;71:981-5.
31. Marchetti A, Buttitta F, Girlando S, et al. mdm2 gene alterations and mdm2 protein expression in breast carcinomas. J Pathol 1995;175:31-8.
32. Spyratos F, Delarue JC, Andrieu C, et al. Epidermal growth factor receptors and prognosis in primary breast cancer. Breast Cancer Res Treat 1990;17:83-9.
33. Gray JW, Collins C, Henderson IC, et al. Molecular cytogenetics of human breast cancer. Cold Spring Harb Symp Quant Biol 1994;59:645-52.
34. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
35. Sauter G, Simon R, Hillan K. Tissue microarrays in drug discovery. Nat Rev Drug Discov 2003;2:962-72.
36. Torhorst J, Bucher C, Kononen J, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001;159:2249-56.
37. Pinkel D, Segraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 1998;20:207-11.
38. Solinas-Toldo S, Lampel S, Stilgenbauer S, et al. Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances. Genes Chromosomes Cancer 1997;20:399-407.
39. Chearskul S, Onreabroi S, Churintrapun M, Semprasert N, Bhothisuwan K. Immunohistochemical study of c-erbB-2 expression in primary breast cancer. Asian Pac J Allergy Immunol 2001;19:197-205.
40. Tulbah AM, Ibrahim EM, Ezzat AA, et al. HER-2/Neu overexpression does not predict response to neoadjuvant chemotherapy or prognosticate survival in patients with locally advanced breast cancer. Med Oncol 2002;19:15-23.
41. Camp RL, Dolled-Filhart M, King BL, Rimm DL. Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. Cancer Res 2003;63:1445-8.
42. Bandyopadhyay D, Redkar A, Bharde S, Dani H, Sampat M, Mittra I. Prognostic association of c-erbB-2 oncogene amplification and protein overexpression in human breast cancer using archival tissues. A comparative study. Acta Oncol 1994;33:493-8.
43. An HX, Niederacher D, Beckmann MW, et al. ERBB2 gene amplification detected by fluorescent differential polymerase chain reaction in paraffin-embedded breast carcinoma tissues. Int J Cancer 1995;64:291-7.
44. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing-ational Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst (Bethesda) 2002;94:852-4.
45. Perez EA, Roche PC, Jenkins RB, et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc 2002;77:148-54.
46. Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst (Bethesda) 2002;94:855-7.
47. Bartlett JM, Going JJ, Mallon EA, et al. Evaluating HER2 amplification and overexpression in breast cancer. J Pathol 2001;195:422-8.
48. Harada Y, Katagiri T, Ito I, et al. Genetic studies of 457 breast cancers. Clinicopathologic parameters compared with genetic alterations. Cancer (Phila) 1994;74:2281-6.
49. Ottestad L, Andersen TI, Nesland JM, et al. Amplification of c-erbB-2, int-2 and c-myc genes in node-negative breast carcinomas. Relationship to prognosis. Acta Oncol 1993;32:289-94.
50. Garcia I, Dietrich PY, Aapro M, Vauthier G, Vadas L, Engel E. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas. Cancer Res 1989;49:6675-9.
51. Tavassoli M, Quirke P, Farzaneh F, Lock NJ, Mayne LV, Kirkham N. c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumour grade, in human breast carcinoma. Br J Cancer 1989;60:505-10.
52. Roux-Dosseto M, Romain S, Dussault N, et al. c-myc gene amplification in selected node-negative breast cancer patients correlates with high rate of early relapse. Eur J Cancer 1992;28A:1600-4.
53. Shousha S. Medullary carcinoma of the breast and BRCA1 mutation. Histopathology 2000;37:182-5.
54. Simon R, Panussis S, Maurer R, et al. KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations. Clin Cancer Res 2004;10:178-83.
55. Marchetti A, Buttitta F, Pellegrini S, et al. p53 mutations and histological type of invasive breast carcinoma. Cancer Res 1993;53:4665-9.
56. Reinfuss M, Stelmach A, Mitus J, Rys J, Duda K. Typical medullary carcinoma of the breast: a clinical and pathological analysis of 52 cases. J Surg Oncol 1995;60:89-94.
57. Courjal F, Louason G, Speiser P, Katsaros D, Zeillinger R, Theillet C. Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int J Cancer 1996;69:247-53.